Skip to content
Brand Protocol

Premenopausal: Very Low E2 + Progesterone <2ng/mL (A/B)

Protocols Brand Protocols Dutch Test
Premenopausal: Very Low E2 + Progesterone <2ng/mL (A/B)

Disclaimer

The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Upload this protocol

Protocol: Very Low E2 + Progesterone <2ng/mL (A/B)

General Protocol (no or low symptoms):

  • Vitamin B6
  • Vitex Agnus Castus Extract
  • Vitamin A
  • Vitamin E

Further considerations:
E2 results within or below the postmenopausal range may imply ovarian failure. Test LH + FSH (blood).

Additional Protocol (low symptoms):

  • Consider phytoestrogens:
    • Black Cohosh Extract
    • Dong Quai Extract
    • Genistein
    • Daidzein
    • Red Clover Extract

Note: the products selected for the protocol are based on the above ingredients and the most commonly recommended by practitioners in the Fullscript community.

Lab Assessments: Progesterone | Estrogen

Assessing Estrogen Status:
Estrogen status (low, normal, or high) is primarily based on the hormone estradiol (E2). Postmenopausal women make about 10 times less estrogen, mostly of adrenal origin. While E2 is the strongest estrogen, estrone (E1) and 16-OH-E1 are also significantly estrogenic. Carefully consider all estrogen metabolites, but give more weight to the levels of E2.

“Optimal” levels may depend on many factors, including the corresponding Pg values and patient history and symptoms. This guide may not be appropriate for women on HRT and the categorizations are made assuming women are NOT on HRT.

 

Assessing Estrogen Metabolites:
Estrogen metabolites must also be considered. E1 and E2 are both metabolized by three competing (2, 4, and 16-OH) pathways. Generally, metabolism that heavily favors 4-OH is considered a potential risk factor for estrogen-related cancers (although this is a complicated issue). Conversely, 2-OH metabolites (particularly 2-methoxy estrogens) are considered more protective.

“Poor Phase 1 Metabolism” on page 11 and 12 generally refers to a pattern that favors 4-OH or 16-OH estrogens over the more protective 2-OH estrogens. “Poor Methylation” refers to a patient who is not readily converting “hydroxy estrogens” (like 2-OH-E1) to “methylated estrogens” (2-methoxy-E1). Both of these patterns can be assessed on the estrogen metabolism page of the DUTCH test.

*Some scenarios on this guide may suggest Hormone Replacement Therapy (HRT). All HRT may have risks which must be understood by a provider before considering any HRT.


Assessing Progesterone Status:

Progesterone (Pg) is categorized into four groups for women:

  • 0-0.5ng/mL – The adrenal glands make most of the Pg after the ovaries quit. If levels are very low, adrenal and ovarian hormone product of Pg may both be low.
  • 0.5-2.0ng/mL – The normal range for a woman who is not cycling/ovulating and has proper adrenal Pg production.
  • 2.0-6.0ng/mL – Most likely represents one of the following scenarios: A) A woman who has ovulated but makes insufficient Pg for a premenopausal woman. B) A postmenopausal or anovulatory woman whose adrenal production of Pg is slightly higher than normal.
  • >6.0ng/mL – Women with levels above 6.0ng/mL have likely recently ovulated. We consider >12.0ng/mL to be strong Pg production.

Note: The Pg assessment is based off of two urine metabolites (a – Pregnanediol and b – Pregnanediol) that are extrapolated to provide an individual “serum equivalent” number that has been shown to correlate to serum Pg measurements.

Disclaimer

The Fullscript Integrative Medical Advisory team has developed or collected these protocols from practitioners and supplier partners to help health care practitioners make decisions when building treatment plans. By adding this protocol to your Fullscript template library, you understand and accept that the recommendations in the protocol are for initial guidance and may not be appropriate for every patient.

Upload this protocol

Fullscript content philosophy

At Fullscript, we are committed to curating accurate, and reliable educational content for practitioners and patients alike. Our educational offerings cover a broad range of topics related to integrative medicine, such as supplement ingredients, diet, lifestyle, and health conditions.

Medically reviewed by expert practitioners and our internal Integrative Medical Advisory team, all Fullscript content adheres to the following guidelines:

  1. In order to provide unbiased and transparent education, information is based on a research review and obtained from trustworthy sources, such as peer-reviewed articles and government websites. All medical statements are linked to the original reference and all sources of information are disclosed within the article.
  2. Information about supplements is always based on ingredients. No specific products are mentioned or promoted within educational content.
  3. A strict policy against plagiarism is maintained; all our content is unique, curated by our team of writers and editors at Fullscript. Attribution to individual writers and editors is clearly stated in each article.
  4. Resources for patients are intended to be educational and do not replace the relationship between health practitioners and patients. In all content, we clearly recommend that readers refer back to their healthcare practitioners for all health-related questions.
  5. All content is updated on a regular basis to account for new research and industry trends, and the last update date is listed at the top of every article.
  6. Potential conflicts of interest are clearly disclosed.